An interventional study of neurological, neuropsychological and MRI evaluation in Cerebral Amyloid Angiopathy, sponsored by University Hospital, Toulouse. Completed at 4 sites in France. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.
Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cerebral Amyloid Angiopathy with a site in France — none open to participants now, none under way, none of them phase 3. Cerebral Amyloid Angiopathy · France.
Among the 10 studies in Cerebral Amyloid Angiopathy with a site in France, this one is the only one that started in 2018, is one of 3 with no phase, and was the 4th registered.
37 studies on the registry are indexed under Cerebral Amyloid Angiopathy; 8 are open to participants now.
Browse Cerebral Amyloid Angiopathy studies →None of the 10 studies in Cerebral Amyloid Angiopathy with a site in France is open now. The open studies under Cerebral Amyloid Angiopathy, anywhere →
Of the 7 Cerebral Amyloid Angiopathy studies recruiting now, 6 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2018.
This study's enrollment of 170 is above the median of 60 across 17 interventional studies indexed under Cerebral Amyloid Angiopathy.
Median enrollment 53 across the 4 interventional studies, 86 across the 6 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 10 have an industry lead sponsor. The 3 most frequent:
University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.
University Hospital, Toulouse has 2 studies filed under Cerebral Amyloid Angiopathy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cerebral Amyloid Angiopathy with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in the elderly with high risk of recurrence.
The investigators aim to determine the relationship between cortical superficial siderosis (cSS), a MRI hemorrhagic marker of CAA and the risk of symptomatic ICH recurrence in a multicentric prospective cohort of patients with acute lobar ICH related to CAA. The investigators hypothesize that patients with cSS have an increased risk of recurrent symptomatic ICH relative to those without cSS.
Patients with acute lobar ICH fulfilling the Boston criteria for probable or possible CAA will be enrolled within 30 days after ICH onset. Brain MRI performed at baseline will be analyzed blinded to clinical data. Patients with presence of cSS will be compared with those without cSS.
During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation. The investigators will compare the rate of recurrent symptomatic ICH at 24 months in patients with vs. without cSS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
Other: neurological, neuropsychological and MRI evaluation
During a systematic follow-up of 24 months, patients will undergo neurological, neuropsychological and MRI evaluation
Other: neurological, neuropsychological and MRI evaluation
neurological, neuropsychological and MRI evaluation
Recurrent symptomatic intracerebral hemorrhage at 24 months
Recurrent symptomatic intracerebral haemorrhage is defined as a further intracerebral hemorrhage documented by CT scan or MRI, associated with new neurologic symptoms
Time frame: 24 months
Recurrent symptomatic ICH at 12 months
Recurrent symptomatic intracerebral haemorrhage is defined as a further intracerebral hemorrhage documented by CT scan or MRI, associated with new neurologic symptoms.
Time frame: 12 months
Transient Focal Neurological Episodes (TFNE) at 12 and 24 months
TFNE was defined as transient (≤24 hours), with fully resolving, focal neurological symptoms that had no known alternative explanation other than CAA (e.g., structural brain lesion, atrial fibrillation, extracranial, or intracranial stenosis)
Time frame: 12 and 24 months
mortality or dependance at 12 and 24 months
Mortality and dependence defined by a modified Rankin scale \>2
Time frame: 12 and 24 months
Cognitive decline at 12 and 24 months
moderate or severe vascular cognitive disorders (VCD) according to the VASCOG criteria.
Time frame: 12 and 24 months
New MRI hemorrhagic lesion at 12 months
Presence of new symptomatic or asymptomatic hemorrhagic lesion (ICH, microbleeds, convexity subarachnoid hemorrhage) on follow-up MRI at 12 months
Time frame: 12 months
Extent of cortical superficial siderosis at 12 months
Extent of cSS is assessed on follow up MRI at 12 months according to the current guidelines: 0: no cSS; 1: focal cSS (restricted to ≤3 sulci); 2: disseminated cSS (≥4 sulci).
Time frame: 12 months
frequency of APOE ε2 and ε4 allele
frequency of both ε2 and ε4 allele on Apolipoprotein E (APOE) genotype at baseline
Time frame: baseline
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2018 to primary completion in Feb 2025, 75 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Toulouse →